- Home
- PRGS vs OGN Comparison
PRGS vs OGN Comparison
Compare PRGS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGS
- OGN
- Stock Information
- Founded
- PRGS 1981
- OGN 1923
- Country
- PRGS United States
- OGN United States
- Employees
- PRGS N/A
- OGN N/A
- Industry
- PRGS Computer Software: Prepackaged Software
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- PRGS Technology
- OGN Health Care
- Exchange
- PRGS Nasdaq
- OGN Nasdaq
- Market Cap
- PRGS 2.1B
- OGN 2.5B
- IPO Year
- PRGS 1991
- OGN N/A
- Fundamental
- Price
- PRGS $50.82
- OGN $10.21
- Analyst Decision
- PRGS Buy
- OGN Hold
- Analyst Count
- PRGS 7
- OGN 4
- Target Price
- PRGS $72.86
- OGN $18.00
- AVG Volume (30 Days)
- PRGS 1.5M
- OGN 3.6M
- Earning Date
- PRGS 06-30-2025
- OGN 08-05-2025
- Dividend Yield
- PRGS 0.34%
- OGN 0.78%
- EPS Growth
- PRGS N/A
- OGN N/A
- EPS
- PRGS 1.30
- OGN 2.88
- Revenue
- PRGS $869,017,000.00
- OGN $6,294,000,000.00
- Revenue This Year
- PRGS $31.04
- OGN N/A
- Revenue Next Year
- PRGS $1.70
- OGN $1.11
- P/E Ratio
- PRGS $39.09
- OGN $3.54
- Revenue Growth
- PRGS 22.10
- OGN N/A
- 52 Week Low
- PRGS $47.42
- OGN $8.01
- 52 Week High
- PRGS $70.56
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- PRGS 39.85
- OGN 58.77
- Support Level
- PRGS $47.42
- OGN $9.55
- Resistance Level
- PRGS $49.00
- OGN $10.22
- Average True Range (ATR)
- PRGS 1.31
- OGN 0.30
- MACD
- PRGS 0.31
- OGN 0.04
- Stochastic Oscillator
- PRGS 53.97
- OGN 93.64
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.